Organogenesis Holdings Inc.

Organogenesis Holdings Inc. (Nasdaq: ORGO) is a regenerative medicine company specializing in advanced wound care that became publicly traded through a SPAC business combination completed in 2018. Headquartered in Canton, Massachusetts, the company develops and commercializes bioactive and acellular wound care products serving the healthcare sector. On August 19, 2019, Organogenesis filed an 8-K current report with the SEC under accession number 0001193125-19-224552, representing a material disclosure in the period following its SPAC combination. The company continues to operate as a publicly traded entity in the regenerative medicine and advanced wound care industry. Sign up on SpacDesk for full filing history, data, and analytics on Organogenesis Holdings and the broader SPAC market.